Skip to main content
OpenTrials
Completed

NCT Number: NCT01813929

Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes

Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). The purpose of this study is to measure the effect of metformin on insulin sensitivity, vascular function and compliance, and mitochondrial function in T1D. The long term goal is to identify novel non-glycemic approaches to managing cardiovascular disease risk in T1D. The results of this study may validate a novel approach to T1D treatment that could significantly improve current management of cardiovascular disease risk in this high risk population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–59 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Colorado Denver

Aurora, Colorado, 80045, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 20-59 years of age,
  • Type 1 diabetes based on antibody-positivity, rapid persistent conversion to insulin requirement after diagnosis, absent C-peptide, or DKA at diagnosis, or a clinical course consistent with T1D,
  • HbA1c 6.0 - 9.5, and
  • Willing and able to commit to two 6 week-long periods of blinded medication followed by hyperinsulinemic euglycemic clamp, vascular testing, and muscle biopsies.

Exclusion criteria

  • Any comorbid condition associated with:
  • inflammation,
  • insulin Resistance, or
  • dyslipidemia including:
  • cancer,
  • heart failure,
  • active or end stage liver disease,
  • kidney disease, or
  • rheumatological disease;
  • Tobacco use;
  • Pregnancy or women who are breastfeeding;
  • Steroid use;
  • Scheduled strenuous physical activity >3 days a week;
  • Angina, known CAD, or any other cardiovascular or pulmonary disease;
  • A history of COPD or asthma;
  • Presence of systolic blood pressure >190 at rest or >250 with exercise, or diastolic pressure >95 at rest or >105 with exercise;
  • Untreated thyroid disease;
  • Proteinuria (urine protein >200 mg/dl) or a creatinine > 1.5 mg/dl (males) or 1.4 mg/dL (females), suggestive of severe renal disease;
  • Severe Proliferative retinopathy;
  • Niacin treatment;
  • Administration of experimental agent for T1D within 30 days prior to screening;
  • Recent (prior 6 months) or current metformin or thiazolidenedione use;
  • Hypoglycemia unawareness or recurrent severe hypoglycemia (no symptoms of hypoglycemia with FSBS<40 and episodes of this severity >1 per week);
  • Weight instability (weight change >5% in last 6 months);
  • History of any organ transplant, including islet cell transplant;
  • Current or prior infection with HIV, hepatitis B or hepatitis C or hepatic -insufficiency (AST or ALT > 2x the upper limits of normal);
  • Any condition, medical or otherwise that would, in the opinion of the investigator, prevent complete participation in the study, or that would pose a significant hazard to the subject;
  • History of substance abuse within the 12 months prior to screening.

Treatment and study plan

metformin

Drug

Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.

Other names: glucophage

Placebo

Drug

Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.

Primary outcomes

  1. Insulin Sensitivity by Hyperinsulinemic Euglycemic Clamp

    Time frame: End of each 6 week intervention period

    Determine the effect of metformin on insulin sensitivity in T1D. Reported measure is glucose infusion rate during hyperinsulinemic euglycemic clamp normalized to total body weight. For this measure, insulin was infused at 40 mU/m2 surface area. Blood sugar wass checked every 5 minutes and glucose infusion adjusted to maintain glucose level at 90 mg/dL for 2 hours. The glucose infusion rate for the final 30 minutes is reported as GIR (aka M-value or glucose disposal rate) in mg glucose/kg*min. A higher value corresponds to greater sensitivity to insulin. There is no strictly defined normal range.

  2. Flow-mediated Brachial Artery Dilation

    Time frame: End of each 6 week intervention period

    Measure of endothelial function by brachial ultrasound of the percent dilation after 5 minutes of occlusion.

Secondary outcomes

  1. Arterial Stiffness by PWV

    Time frame: End of each 6 week intervention period

    Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec.

  2. Arterial Stiffness by AI@75

    Time frame: End of each 6 week intervention period

    Augmentation index by Sphygmacor is a measure of aortic arterial stiffness. AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.

  3. Mitochondrial Measures: Oxygen Consumption

    Time frame: End of each 6 week intervention period

    Oxygen consumption rate with various substrates and max uncoupled O2 consumption.

    Measure is performed on permeabilized muscle fibers from biopsy tissue from the vastus lateralis using the Oroboros OxygraphO2k high resolution respirometer. State 3 is full coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. state 4 is after addition of oligomycin to inhibit the ATP synthase and thus corresponds to the maximum leak state where O2 consumption is limited by the buildup of the proton gradient and can only proceed as fast as the protons can leak back across the membrane. FCCP is added as an uncoupler, allowing free leakage of protons across the inner membrane, and thus measures maximum possible O2 flux. There are no defined normal ranges, but higher state 3 and uncoupled flux indicate better mitochondrial function, while state 4 is needed to correct state 3 to the fully coupled flux.

  4. Mitochondrial Measures: Protein Expression Levels of Electron Transport Chain Complexes

    Time frame: End of each 6 week intervention period

    Mito content by Western Blotting of electron transport chain complexes I, II, III, and V. complex 1 utilizes NADH from pyruvate/malate/glutamate while complex II utilizes FADH from succinate. complex III is the cytochrome c reductase while complex V is the ATP synthase.

  5. Inflammatory Marker: hsCRP

    Time frame: End of each 6 week intervention period

    hsCRP (mg/L) by Beckman Coulter assay

  6. Heart Rate Variability

    Time frame: End of each 6 week intervention period

    measure of autonomic function: ratio of fastest to slowest heart rate during valsalva maneuver

  7. Continuous Glucose Monitor Measures of Mean Glucose

    Time frame: Last Week of each 6 Week Intervention Period (over 7 days)

    Mean Glucose & Glucose Standard Deviation (Glycemic Variability) by Dexcom CGM

  8. Continuous Glucose Monitor Measures of Hypoglycemia

    Time frame: Last Week of each 6 Week Intervention Period (over 7 days)

    Percent of time less than 70 mg/dL during the final week of each phase by Dexcom CGM.

  9. Metabolic Markers: Glucagon

    Time frame: End of each 6 week intervention period

    Glucagon (pg/ml); baseline on AM of each phase final study visit.

  10. Metabolic Markers: Glucose, Triglycerides, Cholesterol

    Time frame: End of each 6 week intervention period

    Glucose (mg/dL), triglycerides (mg/dL), cholesterol (mg/dL) at baseline after each phase

  11. Metabolic Markers: Fatty Acids

    Time frame: End of each 6 week intervention period

    fatty acids (microeq/L) at baseline after each phase in the AM of the final visit

  12. Metabolic Markers: Glycerol

    Time frame: End of each 6 week intervention period

    glycerol (micromol/L) at baseline after each phase in the AM of the final phase visit

  13. Metabolic Markers: Insulin

    Time frame: End of each 6 week intervention period

    insulin (microIU/ml) at baseline after each phase in the AM of the final phase visit

  14. Metabolic Markers: Lactate

    Time frame: End of each 6 week intervention period

    lactate (mmol/L) at baseline after each phase in the AM of the final phase visit

  15. Metabolic Markers: Adiponection

    Time frame: End of each 6 week intervention period

    adiponection (microg/ml) at baseline after each phase in the AM of the final phase visit

  16. Vascular Markers: Endothelin-1 (pg/ml)

    Time frame: End of each 6 week intervention period

    endothelin-1 at baseline after each phase in the AM of the final phase visit by peninsula labs radioimmunoassay

  17. In Vivo Mitochondrial Function: Ratio of the Amount of ATP Generated Per Unit of Oxygen Consumed

    Time frame: End of each 6 week intervention period

    Measured by 31P-mass spec. This ratio measures mitochondrial efficiency. The higher the ratio, the more efficiently the individual converts metabolic substrates into ATP, with the ATP then available for energy-demanding cellular processes such as protein synthesis and biomass production

  18. In Vivo Mitochondrial Function: Time Constants

    Time frame: End of each 6 week intervention period

    Measured by 31P-mass spec. ADP time constant and phosphocreatine time constant. ADP time constant is a measure of the time required to convert ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism). A faster recovery is a better outcome; a slower recovery is a worse outcome. Similarly for phosphocreatine.

  19. In Vivo Mitochondrial Function: QMax, VPCr

    Time frame: End of each 6 week intervention period

    Measured by 31P-mass spec. For each measure, a higher value indicates better mitochondrial function. All re calculated from multiple measures from the MRS spectra. These are relatively new research measures and normal values are not known or generally accepted.

    • QMax is theoretical maximum activity.
    • VPCr measures the rate at which PCr is regenerated.
  20. In Vivo Mitochondrial Function: Oxidative Phosphorylation

    Time frame: End of each 6 week intervention period

    Measured by 31P-mass spec. A higher value indicates better mitochondrial function. All re calculated from multiple measures from the MRS spectra. These are relatively new research measures and normal values are not known or generally accepted. Oxidative Phosphorylation measures the rate at which electron transport activity generates phosphorylated energy sources (ATP and PCr)

  21. In Vivo Mitochondrial Function:AnGly

    Time frame: End of each 6 week intervention period

    Measured by 31P-mass spec. Anaerobic glycolysis measures the amount of anaerobic ATP generation for energy. It is generally felt that a higher value here reflects impaired mitochondrial function necessitating greater reliance on anaerobic metabolism.

  22. Cardiac Function

    Time frame: End of each 6 week intervention period

    Cardiac output

Other outcomes

  1. Vascular Markers: PAI-1

    Time frame: End of each 6 week intervention period

    PAI-1 exploratory thromobotic marker.

  2. Vascular Markers: Exploratory

    Time frame: End of each 6 week intervention period

    ICAM

  3. Oxidative Stress Markers

    Time frame: End of each 6 week intervention period

    TBARs, GSSG:GSH ratio

  4. Mitochondrial Measures: Oxidant Generation

    Time frame: End of each 6 week intervention period

    oxidant generation

  5. Inflammatory Markers: Exploratory

    Time frame: End of each 6 week intervention period

    IL6, TNF alpha

  6. Mitochondrial Oxidant Generation

    Time frame: after each 6 week intervention

    exploratory measure looking at H2O2 production. not performed due to equipment not available.

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Collaborators

  • US Department of Veterans Affairs

Registry information

Acronym: MeT1

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Mar 19, 2013
Registry last updated
Jan 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.